<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17612</article-id><article-id pub-id-type="doi">10.15789/2220-7619-CSP-17612</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Coronavirus spike protein fragment-containing chimeric virus-like particles stimulate human dendritic cell maturation</article-title><trans-title-group xml:lang="ru"><trans-title>Химерные вирусоподобные частицы, содержащие фрагмент белка шипа коронавируса, стимулируют созревание дендритных клеток человека</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Talayev</surname><given-names>V. Yu.</given-names></name><name xml:lang="ru"><surname>Талаев</surname><given-names>В. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Professor, Head of the Laboratory of Cellular Immunology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. лабораторией клеточной иммунологии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher, Laboratory of Immunochemistry</p></bio><bio xml:lang="ru"><p>к.б.н., доцент, ведущий научный сотрудник лаборатории иммунохимии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zaichenko</surname><given-names>I. Ye.</given-names></name><name xml:lang="ru"><surname>Заиченко</surname><given-names>И. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher, Laboratory of Cellular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., ведущий научный сотрудник лаборатории клеточной иммунологии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Svetlova</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Светлова</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Senior Researcher, Laboratory of Cellular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., старший научный сотрудник лаборатории клеточной иммунологии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Voronina</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Воронина</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Senior Researcher, Laboratory of Cellular Immunology</p></bio><bio xml:lang="ru"><p>к.б.н., старший научный сотрудник лаборатории клеточной иммунологии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Babaykina</surname><given-names>O. N.</given-names></name><name xml:lang="ru"><surname>Бабайкина</surname><given-names>О. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Senior Researcher, Laboratory of Cellular Immunology</p></bio><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник лаборатории клеточной иммунологии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lapin</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Лапин</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Immunochemistry</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории иммунохимии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Melentiev</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Мелентьев</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Immunochemistry</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории иммунохимии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Novikova</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Новикова</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Biology), Professor, Laboratory of Molecular Epidemiology of Viral Infections</p>
<p> </p></bio><bio xml:lang="ru"><p>д.б.н., профессор, зав. лабораторией молекулярной эпидемиологии вирусных инфекций</p>
<p> </p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kashnikov</surname><given-names>A. Yu.</given-names></name><name xml:lang="ru"><surname>Кашников</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Laboratory of Molecular Epidemiology of Viral Infections</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории молекулярной эпидемиологии вирусных инфекций</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Biology), Professor, Head of the Laboratory of Immunochemistry</p></bio><bio xml:lang="ru"><p>д.б.н., профессор, зав. лабораторией иммунохимии</p></bio><email>talaev@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing</institution></aff><aff><institution xml:lang="ru">ФБУН Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-06-11" publication-format="electronic"><day>11</day><month>06</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-06-05" publication-format="electronic"><day>05</day><month>06</month><year>2024</year></pub-date><volume>14</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>227</fpage><lpage>237</lpage><history><date date-type="received" iso-8601-date="2024-02-29"><day>29</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-06-10"><day>10</day><month>06</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Talayev V.Y., Novikov D.V., Zaichenko I.Y., Svetlova M.V., Voronina E.V., Babaykina O.N., Lapin V.A., Melentiev D.A., Novikova N.A., Kashnikov A.Y., Novikov V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Талаев В.Ю., Новиков Д.В., Заиченко И.Е., Светлова М.В., Воронина Е.В., Бабайкина О.Н., Лапин В.А., Мелентьев Д.А., Новикова Н.А., Кашников А.Ю., Новиков В.В.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Talayev V.Y., Novikov D.V., Zaichenko I.Y., Svetlova M.V., Voronina E.V., Babaykina O.N., Lapin V.A., Melentiev D.A., Novikova N.A., Kashnikov A.Y., Novikov V.V.</copyright-holder><copyright-holder xml:lang="ru">Талаев В.Ю., Новиков Д.В., Заиченко И.Е., Светлова М.В., Воронина Е.В., Бабайкина О.Н., Лапин В.А., Мелентьев Д.А., Новикова Н.А., Кашников А.Ю., Новиков В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/17612">https://iimmun.ru/iimm/article/view/17612</self-uri><abstract xml:lang="en"><p><italic>Introduction.</italic> Viral capsid proteins can assemble into virus-like particles lacking infectivity and bearing parental virus antigens or artificially introduced antigens from other pathogens. At least some of such particles are highly immunogenic and could serve as a platform for promising vaccines. In this work, we assessed an effect of virus-like particles decorated with a SARS-CoV-2 spike protein fragment on human dendritic cell phenotype and functional properties. <italic>Materials and methods.</italic> The virus-like particles were assembled using chimeric molecules obtained by fusing genetic sequences encoding a norovirus major capsid protein VP1 fragment and a coronavirus spike protein fragment, including the receptor-binding domain. Dendritic cells were obtained from monocytes <italic>in vitro</italic>. <italic>Results.</italic> Incubation of immature dendritic cells with virus-like particles induced their phenotypic and functional maturation. The former was revealed by significantly increased expression of HLA-DR, CD80, CD86 and CD83. Dendritic cell phenotype after incubation with virus-like particles at the maximum concentration of 10 μg/ml did not differ significantly from that of mature dendritic cells in positive control. Along with phenotypic maturation, virus-like particles caused a manifold increase in the production of pro-inflammatory tumor necrosis factor-α, anti-inflammatory interleukin-10, as well as interleukin-6, which can stimulate both antibody synthesis and cellular pro-inflammatory reactions. The pronounced stimulation of dendritic cells by virus-like particles coated with coronavirus antigens evidence about successful particle recognition. Finally, we discuss plausible mechanisms for recognition of such virus-like particles by dendritic cell receptors. <italic>Conclusion.</italic> It has been shown that chimeric virus-like particles induced phenotypic and functional dendritic cell maturation, which is manifested by markedly elevated expression of functionally important membrane molecules, as well as a manifold rise in production of cytokines with a wide functional range. In our opinion, the data obtained indicate a promise of using virus-like particles based on norovirus proteins to display SARS-CoV-2 antigens.</p></abstract><trans-abstract xml:lang="ru"><p><italic>Введение.</italic> Белки вирусных капсидов могут собираться в вирусоподобные частицы, которые лишены инфекционности и несут антигены исходных вирусов или искусственно введенные антигены других возбудителей. Как минимум некоторые из этих частиц обладают высокой иммуногенностью и могут служить основой перспективных вакцин. В данной работе оценивали действие химерных вирусоподобных частиц, декорированных фрагментом белка шипа коронавируса SARS-CoV-2, на дендритные клетки человека — наиболее активные антигенпрезентирующие клетки, которые играют ключевую роль в индукции первичного иммунного ответа. <italic>Материалы и методы.</italic> Объектом исследования были вирусоподобные частицы, собранные из химерных молекул, содержащих антигены коронавируса SARS-CoV-2. Химерные молекулы были получены с помощью слияния генетической последовательности, кодирующей фрагмент основного капсидного белка VP1 норовируса, с последовательностью, кодирующей фрагмент коронавирусного белка шипа, включая рецептор-связывающий домен. Дендритные клетки получали из моноцитов традиционным способом, и оценивали действие частиц на фенотип и функциональные свойства дендритных клеток в условиях <italic>in vitro</italic>. <italic>Результаты.</italic> Инкубация незрелых дендритных клеток с вирусоподобными частицами индуцировала фенотипическое и функциональное созревание клеток. Фенотипическое созревание проявлялось в значительном росте экспрессии молекулы главного комплекса гистосовместимости HLA-DR, ко-стимулирующих молекул CD80 и CD86, а также маркера зрелости CD83. Фенотип дендритных клеток после инкубации с вирусоподобными частицами в максимальной использованной концентрации 10 мкг/мл не имел достоверных отличий от фенотипа зрелых дендритных клеток положительного контроля. Наряду с фенотипическим созреванием вирусоподобные частицы вызывали многократное усиление продукции провоспалительного фактора некроза опухоли-α, противовоспалительного интерлейкина-10, а также интерлейкина-6, который может стимулировать синтез антител, созревание Т-хелперов 17 типа и воспалительные реакции. Выраженная стимуляция дендритных клеток вирусоподобными частицами, покрытыми антигенами коронавируса, свидетельствует об успешном распознавании частиц. В обсуждении приводятся возможные механизмы распознавания структур исследуемых вирусоподобных частиц рецепторами дендритных клеток. <italic>Заключение.</italic> Показано, что химерные вирусоподобные частицы индуцируют фенотипическое и функциональное созревание дендритных клеток, которое проявляется в значительном росте экспрессии функционально значимых мембранных молекул, а также в многократном усилении продукции цитокинов с широким спектром функций. По нашему мнению, полученные результаты свидетельствуют о перспективности использования вирусоподобных частиц на основе норовирусных белков для экспонирования антигенов коронавируса SARS-CoV-2.</p></trans-abstract><kwd-group xml:lang="en"><kwd>virus-like particles</kwd><kwd>coronavirus</kwd><kwd>norovirus</kwd><kwd>dendritic cells</kwd><kwd>vaccine</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вирусоподобные частицы</kwd><kwd>коронавирус</kwd><kwd>норовирус</kwd><kwd>дендритные клетки</kwd><kwd>вакцина</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Новиков Д.В., Мелентьев Д.А., Мохонов В.В., Кашников А.Ю., Новикова Н.А., Лапин В.А., Мохонова Е.В., Новиков В.В. Получение вирусоподобных частиц норовируса (Caliciviridae: Norovirus), содержащих белок VP1 энтеровируса Echovirus 30 (Picornaviridae: Enterovirus: Enterovirus B) // Вопросы вирусологии. 2021. Т. 66, № 5. C. 383–389. [Novikov D.V., Melentev D.A., Mokhonov V.V., Kashnikov A.Y., Novikova N.A., Lapin V.A., Mokhonova E.V., Novikov V.V. Construction of norovirus (Caliciviridae: Norovirus) virus-like particles containing VP1 of the Echovirus 30 (Picornaviridae: Enterovirus: Enterovirus B). Voprosy virusologii = Problems of Virology, 2021, vol. 66, no. 5, рр. 383–389. (In Russ.)] doi: 10.36233/0507-4088-79</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Талаев В.Ю., Заиченко И.Е., Бабайкина О.Н., Светлова М.В., Воронина Е.В. Пути эндоцитоза вирусоподобных частиц и презентация поглощенных антигенов // Инфекция и иммунитет. 2023. Т. 13, № 2. C. 219–233. [Talayev V.Yu., Zaichenko I.Ye., Babaykina O.N., Svetlova M.V., Voronina E.V. Virus-like particle endocytosis pathways and presentation of captured antigens. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2023, vol. 13, no. 2, pp. 219–233. (In Russ.)] doi: 10.15789/2220-7619-VPE-8045</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Талаев В.Ю., Светлова М.В., Заиченко И.Е., Бабайкина О.Н., Воронина Е.В., Чистяков С.И. Взаимодействие В-клеточных рецепторов и антигенов с различным пространственным расположением // Инфекция и иммунитет. 2023. Т. 13, № 5. C. 809–821. [Talayev V.Yu., Svetlova M.V., Zaichenko I.Ye., Babaykina O.N., Voronina E.V., Chistyakov S.I. Interaction of B-cell receptors and antigens with different spatial arrangement. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2023, vol. 13, no. 5, pp. 809–821. (In Russ.)] doi: 10.15789/2220-7619-EOB-14033</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Baric R.S., Yount B., Lindesmith L., Harrington P.R., Greene S.R., Tseng F.C., Davis N., Johnston R.E., Klapper D.G., Moe C.L. Expression and self-assembly of Norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J. Virol., 2002, vol. 76, no. 6, pp. 3023–3030. doi: 10.1128/jvi.76.6.3023-3030.2002</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Barreda D., Santiago C., Rodríguez J.R., Rodríguez J.F., Casasnovas J.M., Mérida I., Ávila-Flores A. SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells. Cells, 2021, vol. 10, no. 12: 3279. doi: 10.3390/cells10123279</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Battin C., De Sousa Linhares A., Paster W., Isenman D.E., Wahrmann M., Leitner J., Zlabinger G.J., Steinberger P., Hofer J. Neuropilin-1 Acts as a Receptor for Complement Split Products. Front. Immunol., 2019, vol. 10: 2209. doi: 10.3389/fimmu.2019.02209</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T., Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Österlund P., Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B., Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O., Stadelmann C., Balistreri G., Simons M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 2020, vol. 370, no. 6518, pp. 856–860. doi: 10.1126/science.abd2985</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chen R., Neill J.D., Noel J.S., Hutson A.M., Glass R.I., Estes M.K., Prasad B.V. Inter- and intragenus structural variations in caliciviruses and their functional implications. J. Virol., 2004, vol. 78, no. 12, pp. 6469–6479. doi: 10.1128/JVI.78.12.6469-6479.2004</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J. Med. Virol., 2020, vol. 92, no. 10, pp. 2105–2113. doi: 10.1002/jmv.25987</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Curreli S., Wong B.S., Latinovic O., Konstantopoulos K., Stamatos N.M. Class 3 semaphorins induce F-actin reorganization in human dendritic cells: Role in cell migration. J. Leukoc. Biol., 2016, vol. 100, no. 6, pp. 1323–1334. doi: 10.1189/jlb.2A1114-534R</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K., Antón-Plágaro C., Shoemark D.K., Simón-Gracia L., Bauer M., Hollandi R., Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A., Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J., Yamauchi Y. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science, 2020, vol. 370, no. 6518, pp. 861–865. doi: 10.1126/science.abd3072</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hardy M.E. Norovirus protein structure and function. FEMS Microbiol. Lett., 2005, vol. 253, no. 1, pp. 1–8. doi: 10.1016/j.femsle.2005.08.031</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines, 2010, vol. 9, no. 3, pp. 299–307. doi: 10.1586/erv.09.163</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Jiang X., Wang M., Graham D.Y., Estes M.K. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol., 1992, vol. 66, no. 11, pp. 6527–6532. doi: 10.1128/JVI.66.11.6527-6532.1992</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol., 2020, vol. 5, no. 4, pp. 562–569. doi: 10.1038/s41564-020-0688-y</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J. Virol., 2015, vol. 89, no. 4, pp. 1954–1964. doi: 10.1128/JVI.02615-14</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, vol. 397, no. 10275, pp. 671–681. doi: 10.1016/S0140-6736(21)00234-8</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Malik Y.A. Properties of Coronavirus and SARS-CoV-2. Malays. J. Pathol., 2020, vol. 42, no. 1, pp. 3–11.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mobini S., Chizari M., Mafakher L., Rismani E., Rismani E. Structure-based study of immune receptors as eligible binding targets of coronavirus SARS-CoV-2 spike protein. J. Mol. Graph. Model., 2021, vol. 108: 107997. doi: 10.1016/j.jmgm.2021.107997</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Mohsen M.O., Gomes A.C., Vogel M., Bachmann M.F. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines, 2018, vol. 6, no 3, pp. 37. doi: 10.3390/vaccines6030037</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Pang H.B., Braun G.B., Friman T., Aza-Blanc P., Ruidiaz M.E., Sugahara K.N., Teesalu T., Ruoslahti E. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun., 2014, vol. 5: 4904. doi: 10.1038/ncomms5904</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Prasad B.V., Hardy M.E., Dokland T., Bella J., Rossmann M.G., Estes M.K. X-ray crystallographic structure of the Norwalk virus capsid. Science, 1999, vol. 286, pp. 287–290. doi: 10.1126/science.286.5438.287</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Prasad B.V., Rothnagel R., Jiang X., Estes M.K. Three-dimensional structure of baculovirus-expressed Norwalk virus capsids. J. Virol., 1994, vol. 68, pp. 5117–5125. doi: 10.1128/jvi.68.8.5117-5125.1994</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Rando H.M., Lordan R., Lee A.J., Naik A., Wellhausen N., Sell E., Kolla L., COVID-19 Review Consortium, Gitter A., Greene C.S. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. mSystems, 2023, vol. 8, no. 2: e0092722. doi: 10.1128/msystems.00927-22</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 1994, vol. 179, pp. 1109–1118. doi: 10.1084/jem.179.4.1109</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Santi L., Batchelor L., Huang Z., Hjelm B., Kilbourne J., Arntzen C.J., Chen Q., Mason H.S. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine, 2008, vol. 26, no. 15, pp. 1846–1854. doi: 10.1016/ j.vaccine.2008.01.053</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Song X., Hu W., Yu H., Zhao L., Zhao Y., Zhao X., Xue H.H., Zhao Y. Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages. Cytometry A, 2023, vol. 103, no. 2, pp. 136–145. doi: 10.1002/cyto.a.24285</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 1991, vol. 9, pp. 271–296. doi: 10.1146/annurev.iy.09.040191.001415</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Talayev V., Zaichenko I., Svetlova M., Matveichev A., Babaykina O., Voronina E., Mironov A. Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity. Vaccine, 2020, vol. 38, no. 42, pp. 6645–6655. doi: 10.1016/j.vaccine.2020.07.053</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Tan M., Jiang X. The p-domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J. Virol., 2005, vol. 79, pp. 14017–14030. doi: 10.1128/JVI.79.22.14017-14030.2005</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Teesalu T., Sugahara K.N., Kotamraju V.R., Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl Acad. Sci. USA, 2009, vol. 106, no. 38, pp. 16157–16162. doi: 10.1073/pnas.0908201106</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Tordjman R., Lepelletier Y., Lemarchandel V., Cambot M., Gaulard P., Hermine O., Roméo P.H. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol., 2002, vol. 3, no. 5, pp. 477–482. doi: 10.1038/ni789</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Tortorici M.A., Veesler D. Structural insights into coronavirus entry. Adv. Virus. Res., 2019, vol. 105, pp. 93–116. doi: 10.1016/bs.aivir.2019.08.002</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Tulimilli S.V., Dallavalasa S., Basavaraju C.G., Kumar Rao V., Chikkahonnaiah P., Madhunapantula S.V., Veeranna R.P. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines (Basel), 2022, vol. 10, no. 10: 1751. doi: 10.3390/vaccines10101751</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, vol. 181, no. 2, pp. 281–292.e6. doi: 10.1016/j.cell.2020.02.058</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J., Sheng J., Quan L., Xia Z., Tan W., Cheng G., Jiang T. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe, 2020, vol. 27, no. 3, pp. 325–328. doi: 10.1016/j.chom.2020.02.001</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, 2020, vol. 367, no. 6485, pp. 1444–1448. doi: 10.1126/science.abb2762</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, vol. 579, no. 7798, pp. 270–273. doi: 10.1038/s41586-020-2012-7</mixed-citation></ref></ref-list></back></article>
